Moneycontrol PRO

you are here: HomeNewsBusinessEarningsBiosimilar insulin Glargine to make $100 m from FY18: Biocon

SHOW NAMES

Trending Topics

SBI Q1 Results Manappuram Finance Q1 Results Tata Motors Q1 results Titan Q1 Preview SBI Q1 Preview

business

Biosimilar insulin Glargine to make $100 m from FY18: Biocon

Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.

first published: Apr 27, 2016 11:59 am

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347